Pancreatic primitive neuroectodermal tumors: Clinical features, treatment, and influencing factors.

in World journal of gastrointestinal oncology by Yan-Fei He, Huan-Zhi Wang, Xiao-Dong Hu, Jun-Qiang Liu, Hu-Ming Li, Jie Wang, Shuang-Feng Lu

TLDR

  • This study analyzed the clinical characteristics and treatment outcomes of 30 patients with pancreatic primitive neuroectodermal tumors (PNETs) and found that lymph node metastasis was a prognostic factor affecting survival.

Abstract

Data on clinical characteristics, treatment outcomes, and prognosis of pancreatic primitive neuroectodermal tumors (PNETs) are limited. To analyze the clinical data of 30 patients with pancreatic PNETs to identify their clinical characteristics and factors associated with prognosis. We used the keywords "primary neuroectodermal tumor," "digestive tract," "pancreas," "pancreatic," and "gastrointestinal," individually or in combination, to collect data from a global database for all patients with pancreatic PNET to date. Univariate and Cox regression analyses were performed to identify prognostic factors for patient survival. A total of 30 cases of pancreatic PNET were included in this study: 15 males and 15 females with a mean age of 24 years. The main symptom was abdominal pain (73.3%), and the median tumor size was 7.85 cm. Twenty-four patients (80.0%) underwent surgery and nineteen patients received adjuvant therapy. Local metastasis was observed in 13 patients (43.3%), lymph node metastasis in 10 patients (33.3%), and distant metastasis in 6 patients (20.0%). Local recurrence was observed in 13 patients (43.3%). The median survival time of all patients was 29.4 months, and the overall estimated 1-year and 3-year survival rates were approximately 66.0% and 36.4%, respectively. Univariate analysis showed that chemotherapy (= 0.036), local metastasis (= 0.041), lymph node metastasis (= 0.003), distant metastasis (= 0.049), and surgical margins (= 0.048) were the prognostic factors affecting survival. Multivariate analysis revealed only lymph node metastasis (= 0.012) as a prognostic factor. Pancreatic PNET is extremely rare, occurs in young adults, has no apparent sex predisposition, has a high rate of metastasis and early recurrence, and has a very poor prognosis. The diagnosis of pancreatic PNET requires a combination of clinical symptoms, pathologic features, immunohistochemistry, and cytogenetic analysis. Univariate analysis suggested that chemotherapy, metastasis, and surgical margins were prognostic factors affecting survival, and multivariate analysis suggested that lymph node metastasis is an important prognostic factor. Therefore, early diagnosis, early and extensive resection, and adjuvant chemoradiotherapy may help improve prognosis.

Overview

  • This study aimed to analyze the clinical characteristics and treatment outcomes of 30 patients with pancreatic primitive neuroectodermal tumors (PNETs).
  • The study used univariate and Cox regression analyses to identify prognostic factors for patient survival.
  • The primary objective of the study is to identify the clinical characteristics and factors associated with prognosis of pancreatic PNETs.

Comparative Analysis & Findings

  • The study revealed that pancreatic PNET is extremely rare, occurring in young adults with a high rate of metastasis and early recurrence.
  • Univariate analysis showed that chemotherapy, local metastasis, lymph node metastasis, distant metastasis, and surgical margins were prognostic factors affecting survival.
  • Multivariate analysis revealed only lymph node metastasis as a prognostic factor affecting survival.

Implications and Future Directions

  • The study suggests that early diagnosis, early and extensive resection, and adjuvant chemoradiotherapy may help improve prognosis for patients with pancreatic PNET.
  • Future research could investigate the efficacy of different treatment regimens for pancreatic PNET, including the role of chemotherapy and radiation therapy.
  • The study highlights the need for further research on the molecular biology of pancreatic PNET to develop targeted therapies for this aggressive disease.